{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:29:28Z","timestamp":1793806168656,"version":"4.6.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Scientific Research Fund of Education Department of Yunnan Province","award":["2025J0784"],"award-info":[{"award-number":["2025J0784"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Tetrandrine, a bisbenzylisoquinoline alkaloid extracted from\n                      <jats:italic toggle=\"yes\">Stephania tetrandra<\/jats:italic>\n                      S. Moore, is clinically used in the treatment of silicosis and rheumatoid arthritis. Despite its demonstrated efficacy, systematic safety evaluations remain limited. This study represents the first effort to identify adverse event (AE) signals associated with tetrandrine meglumine using the World Health Organization VigiAccess database. Global AE reports for tetrandrine were extracted up to July 6, 2025. The collected data included demographic variables such as age group and gender, as well as regional distribution. Additionally, data on adverse drug reaction-related disease systems and symptoms were compiled from adverse drug reaction annual reports and reports submitted to the World Health Organization. Disproportionality analyses were conducted using the reporting odds ratio (ROR) and the Bayesian confidence propagation neural network. A total of 265 reports were included, documenting 448 AEs. The most commonly affected systems were gastrointestinal disorders (38.39%), skin and subcutaneous tissue disorders (16.96%), and nervous system disorders (16.07%). Frequently reported adverse reactions included nausea, dizziness, pruritus, vomiting, rash, abdominal pain, diarrhea, and abnormal hepatic function. Strong association signals were observed for oral anesthesia (ROR 241.19, 95% confidence interval [CI] 79.74\u2013729.58), abnormal hepatic function (ROR 20.31, 95% CI 12.27\u201333.63), hypoaesthesia (ROR 10.47, 95% CI 4.66\u201323.54), pollakiuria (ROR 9.53, 95% CI 3.04\u201329.83), and abdominal pain (ROR 8.94, 95% CI 5.96\u201313.41). Additionally, potential adverse reactions not listed in the product labeling, including pruritus, rash, abnormal hepatic function, chest pain, palpitations, hypoaesthesia, edema, pyrexia, insomnia, pollakiuria, and dyspnea, were identified. This study comprehensively characterized the AE profile of tetrandrine and identified novel adverse effects. These findings underscore the importance of ongoing drug safety monitoring and patient management, and highlight the need for clinicians to use this medication more appropriately, tailoring treatment regimens based on the identified adverse effect profiles.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050823","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:02:01Z","timestamp":1790359321000},"page":"e50823","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Post-marketing safety assessment of tetrandrine based on the WHO-VigiAccess database"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-7030","authenticated-orcid":false,"given":"Yuanyuan","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Yunnan Province, Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Yunnan Province, Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5748-413X","authenticated-orcid":false,"given":"Chunyue","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Yunnan Province, Kunming, Yunnan, China"},{"name":"College of Pharmacy, Dali University, Dali, Yunnan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1038\/s41467-025-61565-9","article-title":"Tetrandrine regulates NAADP-mediated calcium signaling through a LIMP-2-dependent and sphingosine-mediated mechanism.","volume":"16","author":"Chan","year":"2025","journal-title":"Nat Commun"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00005344-199210000-00001","article-title":"Tetrandrine inhibits both T and L calcium channel currents in ventricular cells.","volume":"20","author":"Liu","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s11655-025-4130-4","article-title":"Research progress on anti-fibrotic effects and mechanisms of tetrandrine.","volume":"31","author":"Ma","year":"2025","journal-title":"Chin J Integr Med"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"e70592","DOI":"10.1096\/fj.202500404R","article-title":"Tetrandrine improves severe acute pancreatitis by inhibiting NCOA4 glycosylation-mediated binding to FTH1 and inducing autophagy-dependent ferroptosis.","volume":"39","author":"Lu","year":"2025","journal-title":"FASEB J"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"156737","DOI":"10.1016\/j.phymed.2025.156737","article-title":"A tri-compound formula comprising Ginsenoside Rg1, tetrandrine and icariin alleviates atopic dermatitis symptoms in a mouse model.","volume":"141","author":"Wu","year":"2025","journal-title":"Phytomedicine"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/WNR.0000000000002171","article-title":"Tetrandrine mediates autophagy via sirtuin 3\/adenosine 5-monophosphate-activated protein kinase\/mammalian target of rapamycin signal pathway to attenuate early brain injury after subarachnoid hemorrhage.","volume":"36","author":"Wang","year":"2025","journal-title":"Neuroreport"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1002\/mco2.206","article-title":"Antiviral effects and tissue exposure of tetrandrine against SARS-CoV-2 infection and COVID-19.","volume":"4","author":"Liu","year":"2023","journal-title":"MedComm (2020)"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"177635","DOI":"10.1016\/j.ejphar.2025.177635","article-title":"Tetrandrine and adriamycin reverse multidrug resistance by regulating NLRP3\/Caspase-1\/GSDMD signaling in human breast cancer cells.","volume":"998","author":"Xin","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/s41401-025-01507-9","article-title":"Tetrandrine augments melanoma cell immunogenicity via dual inhibition of autophagic flux and proteasomal activity enhancing MHC-I presentation.","volume":"46","author":"He","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2147\/IJN.S431599","article-title":"Preparation, characterization, and anti-lung cancer activity of tetrandrine-loaded stealth liposomes.","volume":"19","author":"Fang","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12935-024-03410-5","article-title":"Inhibition of autophagy induced by tetrandrine promotes the accumulation of reactive oxygen species and sensitizes efficacy of tetrandrine in pancreatic cancer.","volume":"24","author":"Wang","year":"2024","journal-title":"Cancer Cell Int"},{"key":"R12-20261104","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3892\/etm.2020.8858","article-title":"Clinical efficacy of acetylcysteine combined with tetrandrine tablets on patients with silicosis and its effect on exercise tolerance and pulmonary function.","volume":"20","author":"Guo","year":"2020","journal-title":"Exp Ther Med"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12890-025-03821-8","article-title":"Tetrandrine slows disease progression on high-resolution computed tomography and lung function decline in artificial stone-associated silicosis: a retrospective cohort study.","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Pulm Med"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"1561020","DOI":"10.3389\/fphar.2025.1561020","article-title":"A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases.","volume":"16","author":"Hu","year":"2025","journal-title":"Front Pharmacol"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"104639","DOI":"10.1016\/j.jbi.2024.104639","article-title":"Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records.","volume":"153","author":"Jeong","year":"2024","journal-title":"J Biomed Inform"},{"key":"R16-20261104","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration.","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"R17-20261104","doi-asserted-by":"crossref","first-page":"1585862","DOI":"10.3389\/fphar.2025.1585862","article-title":"Adverse reactions of four multi-targeted tyrosine kinase inhibitors: a descriptive analysis of the WHO-VigiAccess database.","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"R18-20261104","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/s41401-021-00693-6","article-title":"Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages.","volume":"43","author":"Song","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"R19-20261104","first-page":"205","article-title":"Strategies for the treatment of pneumoconiosis.","volume":"8","author":"Banks","year":"1993","journal-title":"Occup Med"},{"key":"R20-20261104","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.biopha.2017.10.116","article-title":"Tetrandrine and cancer - an overview on the molecular approach.","volume":"97","author":"Bhagya","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2174\/0115680266282360240222062032","article-title":"Tetrandrine for targeting therapy resistance in cancer.","volume":"24","author":"Lima","year":"2024","journal-title":"Curr Top Med Chem"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","article-title":"Incidence and preventability of adverse drug events among older persons in the ambulatory setting.","volume":"289","author":"Gurwitz","year":"2003","journal-title":"JAMA"},{"key":"R23-20261104","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended guidelines for the treatment of cancer treatment-induced diarrhea.","volume":"22","author":"Benson","year":"2004","journal-title":"J Clin Oncol"},{"key":"R24-20261104","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2147\/JHC.S523261","article-title":"Natural bioactive compounds targeting the Wnt\/\u03b2-catenin pathway for the treatment of hepatocellular carcinoma.","volume":"12","author":"Tian","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"issue":"Suppl","key":"R25-20261104","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.clml.2015.02.008","article-title":"Practical management of lenalidomide-related rash.","volume":"15","author":"Tinsley","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R26-20261104","doi-asserted-by":"crossref","first-page":"107069","DOI":"10.1016\/j.bioorg.2023.107069","article-title":"Novel sulfonyl-substituted tetrandrine derivatives for colon cancer treatment by inducing mitochondrial apoptosis and inhibiting PI3K\/AKT\/mTOR pathway.","volume":"143","author":"Ling","year":"2024","journal-title":"Bioorg Chem"},{"key":"R27-20261104","doi-asserted-by":"crossref","first-page":"111700","DOI":"10.1016\/j.biopha.2021.111700","article-title":"Tetrandrine inhibits the occurrence and development of frozen shoulder by inhibiting inflammation, angiogenesis, and fibrosis.","volume":"140","author":"Zhao","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R28-20261104","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00403-025-03930-8","article-title":"Tetrandrine induces cell cycle arrest in cutaneous melanoma cells by inhibiting IL-6\/CDC42 signaling.","volume":"317","author":"Niu","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"R29-20261104","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ptr.8058","article-title":"Tetrandrine promotes the survival of the random skin flap via the PI3K\/AKT signaling pathway.","volume":"38","author":"Wang","year":"2024","journal-title":"Phytother Res"},{"key":"R30-20261104","first-page":"837","article-title":"Prevention and management of adverse events related to regorafenib.","volume":"22","author":"De Wit","year":"2014","journal-title":"Support Care Cancer"},{"key":"R31-20261104","doi-asserted-by":"crossref","first-page":"e0216948","DOI":"10.1371\/journal.pone.0216948","article-title":"Molecular mechanisms involved in drug-induced liver injury caused by urate-lowering Chinese herbs: a network pharmacology study and biology experiments.","volume":"14","author":"Li","year":"2019","journal-title":"PLoS One"},{"key":"R32-20261104","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/aps.2013.62","article-title":"ROS generated by CYP450, especially CYP2E1, mediate mitochondrial dysfunction induced by tetrandrine in rat hepatocytes.","volume":"34","author":"Qi","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"R33-20261104","doi-asserted-by":"crossref","first-page":"154325","DOI":"10.1016\/j.phymed.2022.154325","article-title":"Ursolic acid alleviates tetrandrine-induced hepatotoxicity by competitively binding to the substrate-binding site of glutathione S-transferases.","volume":"104","author":"Chu","year":"2022","journal-title":"Phytomedicine"},{"key":"R34-20261104","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbr.2012.10.015","article-title":"Tetrandrine exerts antidepressant-like effects in animal models: role of brain-derived neurotrophic factor.","volume":"238","author":"Gao","year":"2013","journal-title":"Behav Brain Res"},{"key":"R35-20261104","first-page":"59","article-title":"Secretory, motor and vascular effects in the sublingual gland of the rat caused by autonomic nerve stimulation.","volume":"63","author":"Templeton","year":"1978","journal-title":"Q J Exp Physiol Cogn Med Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:00:51Z","timestamp":1793804451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":35,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050823","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2025-11-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}